Global Gout Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Gout Therapeutics Market Growth (Status and Outlook) 2023-2029

Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries.

LPI (LP Information)' newest research report, the “Gout Therapeutics Industry Forecast” looks at past sales and reviews total world Gout Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Gout Therapeutics sales for 2023 through 2029. With Gout Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gout Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Gout Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gout Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gout Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gout Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gout Therapeutics.

The global Gout Therapeutics market size is projected to grow from US$ 4216.2 million in 2022 to US$ 10190 million in 2029; it is expected to grow at a CAGR of 13.4% from 2023 to 2029.

Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to patients on the basis of severity of the condition. Introduction of urate-lowering agents is one of the primary driver of the gout therapeutics market. First line therapies such as Febuxostat and Allopurinol are now replaced urate-lowering agents such as Lesinurad, which help in reducing pain as well as negotiate the risk of joint destruction. The growing popularity of OTC drugs such as Oral colchicine, corticosteroids, and NASAIDs, which are quite effective in moderate gout indications, are also favoring the global gout therapeutics market in the positive direction. Technological advancements in medical imaging is another factor augmenting the demand in the gout therapeutics market. On the other hand, low levels of physician and patient awareness, heavy dependency on generic drugs, and use of CAM for the treatment of gout are restraining factors over the global gout therapeutics market.

This report presents a comprehensive overview, market shares, and growth opportunities of Gout Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents

Segmentation by application
Acute Gout
Chronic Gout

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda Pharmaceutical Company
Novartis
AstraZeneca
GlaxoSmithKline
Merck
Regeneron Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.